로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Fusion glycoprotein F0

Fusion glycoprotein F0

요약

Name:Respiratory syncytial virus F protein
Target Synonym:Protein F,F,Fusion glycoprotein F0
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

제품 리스트 구매

제품 상태별:
제품 유형별 :
종별:
태그별:
결합물별:
제품번호 제품 설명 구조 순도 특징
RSF-V52H4 Mumps virus Mumps virus (strain Miyahara vaccine) (MuV) Fusion glycoprotein F0, His Tag (MALS verified)
RSF-V52H4-sds

일부의 생물활성 데이터

RSF-V52H4-MALS-HPLC
Fusion glycoprotein F0 MALS images

The purity of Mumps virus (strain Miyahara vaccine) (MuV) Fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H4) is more than 85% and the molecular weight of this protein is around 185-215 kDa verified by SEC-MALS.

Synonym Name

Fusion glycoprotein F0

Background

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation. Both states exhibit epitopes targeted by neutralizing antibodies, and post-fusion RSV F is being developed as a vaccine candidate.

Clinical and Translational Updates

This web search service is supported by Google Inc.

totop